- Home
- CTO vs EYPT Comparison
CTO vs EYPT Comparison
Compare CTO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | EYPT |
|---|---|---|
| Founded | 1902 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.9M | 1.5B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | CTO | EYPT |
|---|---|---|
| Price | $17.82 | $16.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $22.00 | ★ $29.60 |
| AVG Volume (30 Days) | 254.1K | ★ 1.1M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 8.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $146,948,000.00 | $42,339,000.00 |
| Revenue This Year | $20.87 | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.84 | N/A |
| 52 Week Low | $15.07 | $3.91 |
| 52 Week High | $20.88 | $19.11 |
Technical Indicators
Market Signals| Indicator | CTO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 60.28 |
| Support Level | $17.81 | $15.97 |
| Resistance Level | $18.31 | $19.11 |
| Average True Range (ATR) | 0.25 | 0.96 |
| MACD | -0.06 | 0.11 |
| Stochastic Oscillator | 39.72 | 46.36 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.